title: CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
abstract: BACKGROUND
  To evaluate the correlations between CD24 polymorphisms and clinicopathologic variables of patients with breast cancer.
  
  
  METHODS
  Single-nucleotide polymorphisms (SNPs) of CD24 were genotyped by the Sequenom MassArray iPLEX Gold System in 170 patients with breast cancer, and a total of 120 patients with histologically confirmed T2-4N0-2 M0 breast cancer were recruited to therapy with docetaxel, doxorubicin, and cyclophosphamide (TAC) as neoadjuvant chemotherapy. Data were analyzed by the chi-square test and logistic regression analysis.
  
  
  RESULTS
  There were no significant correlations between CD24 polymorphisms and any of the clinicopathologic variables, and no significant associations were found between either of the polymorphisms and CD24 protein expression. The clinical response rate and the pathologic complete response (pCR) rate were 68.8% and 27.1% in patients with the CD24 rs3838646 CA/CA genotype, and 87.5% and 20.8% in CD24 CA/Del and Del/Del genotype. There were no statistically significant differences between the CA/CA group and the Del allele group. The clinical response rate was 85.4% in patients with the CD24 rs52812045 C/C genotype and 63.9% in patients with the CD24 C/T and T/T genotype. There was a statistically significant difference between the C/C group and the T allele group (odds ratio = 0.28; 95% confidence interval, 0.11-0.73, P = .01). The pCR rate was 29.2% in patients with the CD24 rs52812045 C/C genotype and 23.6% in patients with the CD24 C/T and T/T genotype. There were no statistically significant differences between the C/C group and the T allele group. In a multivariate analysis, there was no correlation between CD24 rs3838646 or rs52812045 genotype and pCR.
  
  
  CONCLUSIONS
  CD24 rs3838646 and rs52812045 polymorphism could not predict the pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer. Additional larger studies are required to confirm this finding.
authors.affiliation: Department of Breast Surgery, Chongqing Cancer Institute, People's Republic of China. Electronic address: zhouxin75324@163.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D051927:CD24 Antigen / Q000235:genetics*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D051927:CD24 Antigen; C497889:CD24 protein, human; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide
keywords: Breast cancer; CD24; Chemosensitivity; Neoadjuvant chemotherapy; Polymorphism